市場調査レポート
商品コード
1467694
性感染症診断の市場レポート:タイプ別、デバイスタイプ別、エンドユーザー別、地域別、2024~2032年Sexually Transmitted Disease Diagnostics Market Report by Type, Device Type (Laboratory Devices, Point of Care Devices), End User (Laboratory Testing, Point of Care Testing), and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
性感染症診断の市場レポート:タイプ別、デバイスタイプ別、エンドユーザー別、地域別、2024~2032年 |
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
性感染症診断の世界市場規模は、2023年に1,041億米ドルに達しました。今後、IMARC Groupは、同市場が2032年までに1,595億米ドルに達し、2024~2032年の成長率(CAGR)は4.71%に達すると予測しています。性病有病率の上昇、早期診断に関する大衆の意識の高まり、家庭用性病試験キットの採用は、市場を牽引する主要要因の一つです。
性感染症(STD)診断とは、STDの存在を特定・確認するために行われる試験、試験、綿棒培養を指します。これには、特定のSTDの抗体や抗原の存在を検出するための血液、体液サンプル、尿試験が含まれます。性器ヘルペス、クラミジア、淋病、梅毒、陰部シラミ、トリコモナス、後天性免疫不全症候群(AIDS)、細菌性膣炎、疥癬、下疳など、様々な性感染症や感染症の検出やスクリーニングに広く使用されています。STD診断は、早期発見と正確な治療を助け、不妊症を予防し、胎児を感染から守り、病気の蔓延を最小限に抑えます。これらの診断法はまた、長期的なリスクの可能性を減らし、信頼性を高め、医師が病気やその原因について貴重な洞察を得るのにも役立ちます。
無防備な性交渉や薬剤乱用による性感染症の有病率の上昇は、市場成長を促進する重要な要因の一つです。STD診断は、細菌、ウイルス、寄生虫などの様々なSTD原因物質を高い精度と信頼性で検出するために広く使用されており、医療プロバイダーが適切な治療を決定し、母親から乳幼児への疾患感染を予防し、患者の臨床転帰を改善するのに役立っています。これに加えて、不妊症、先天性障害、がん、失明、骨の奇形、脳の損傷、精神遅滞などの長期的な合併症を予防できるSTDの早期発見・診断に関する大衆の意識の高まりが、もう一つの成長促進要因として作用しています。さらに、教育キャンペーン、セミナー、ソーシャルメディア広告を通じて、性の健康と性病試験に関する意識を高め、それに関連する社会的偏見を取り除くためのさまざまな政府イニシアチブの実施が、市場成長の原動力となっています。さらに、費用対効果が高く、安全で正確かつ便利で、結果が早く得られ、プライバシーが保たれる家庭用STD試験キットの導入が、市場成長にプラスの影響を与えています。さらに、個人の陰部のデジタル画像を分析することで性病を診断できる人工知能(AI)ベースのモバイルアプリケーションが最近開拓され、その結果、性病試験へのアクセスが向上し、機密性が維持され、個人データが保護されるようになったことも、市場成長に好影響を与えています。医療産業の著しい成長、eコマースプラットフォームでのSTD診断キットの容易な入手、新規診断技術の研究開発(R&D)への投資の増加など、その他の要因も市場開拓を促進すると予測されます。
The global sexually transmitted disease (STD) diagnostics market size reached US$ 104.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 159.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.71% during 2024-2032. The rising prevalence of STDs, increasing awareness among the masses regarding early diagnosis, and the introduction of at-home STD testing kits represent some of the key factors driving the market.
Sexually transmitted disease (STD) diagnostics refer to examinations, tests, and swab cultures performed to identify and confirm the presence of STDs. It includes blood, fluid sample, and urine tests to detect the presence of antibodies or antigens of certain STDs. It is widely used to detect and screen various sexually transmitted diseases and infections, such as genital herpes, chlamydia, gonorrhea, syphilis, pubic lice, trichomoniasis, acquired immune deficiency syndrome (AIDS), bacterial vaginosis, scabies, and chancroid. STD diagnostics aids in early detection and accurate treatment, prevents infertility, protects unborn children from infection, and minimizes the spread of diseases. These diagnostic methods also help in reducing the chance of long-term risks, boosting confidence, and providing physicians with valuable insight into diseases and their causes.
The rising prevalence of sexually transmitted diseases (STDs) due to unprotected sexual intercourse and drug abuse is one of the key factors driving the market growth. STD diagnostics are widely used to detect various STD-causing agents, such as bacteria, viruses, and parasites, with high accuracy and reliability that aids healthcare providers in determining suitable treatment, preventing disease transmission from mothers to infants, and improving clinical outcomes for patients. In addition to this, the increasing awareness among the masses regarding early detection and diagnosis of STDs, which can prevent long-term complications, such as infertility, congenital disabilities, cancer, blindness, bone deformities, brain damage, and mental retardation, is acting as another growth-inducing factor. Furthermore, the implementation of various government initiatives to raise awareness regarding sexual health and STD testing and remove the social stigma associated with it through educational campaigns, seminars, and social media advertisements are providing an impetus to the market growth. Additionally, the introduction of at-home STD testing kits that are cost-effective, safe, accurate, and convenient, provide faster results, and maintain privacy is positively influencing the market growth. Moreover, the recent development of artificial intelligence (AI) - based mobile applications that can diagnose STDs by analyzing digital images of an individual's private parts, thus improving access to STD screenings, maintaining confidentiality, and protecting personal data, is favoring the market growth. Other factors, including significant growth in the healthcare industry, easy availability of STD diagnostics kits across e-commerce platforms, and increasing investment in the research and development (R&D) of novel diagnostic technologies, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global sexually transmitted disease (STD) diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, device type, and end user.
Chlamydia Testing
Syphilis Testing
Gonorrhea Testing
Herpes Simplex Virus Testing
Human Papilloma Virus Testing
Human Immunodeficiency Virus Testing
Chancroid Testing
Others
The report has provided a detailed breakup and analysis of the sexually transmitted disease (STD) diagnostics market based on the type. This includes chlamydia, syphilis, gonorrhea, herpes simplex virus, human papilloma virus, human immunodeficiency virus, chancroid testing, and others. According to the report, chlamydia testing represented the largest segment.
Laboratory Devices
Thermal Cycler - PCR
Lateral Flow Readers
Flow Cytometers
Absorbance Microplate Reader - Enzyme Linked Immunosorbent Assay (ELISA)
Others
Point of Care (PoC) Devices
Phone Chips (Microfluidics + ICT)
Portable/Bench Top/Rapid Diagnostic Kits
A detailed breakup and analysis of the sexually transmitted disease (STD) diagnostics market based on the device type has also been provided in the report. This includes laboratory devices (thermal cycler - PCR, lateral flow readers, flow cytometers, absorbance microplate reader - enzyme linked immunosorbent assay (ELISA), and others) and point of care (PoC) devices (phone chips (microfluidic + ICT) and portable/bench top/rapid diagnostic kits). According to the report, laboratory devices accounted for the largest market share.
Laboratory Testing
Point of Care (PoC) Testing
A detailed breakup and analysis of the sexually transmitted disease (STD) diagnostics market based on the end user has also been provided in the report. This includes laboratory and point of care (PoC) testing. According to the report, laboratory testing accounted for the largest market share.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for sexually transmitted disease (STD) diagnostics. Some of the factors driving the North America sexually transmitted disease (STD) diagnostics market included the rising prevalence of STDs, extensive research and development (R&D) activities, and significant growth in the healthcare industry.
The report has also provided a comprehensive analysis of the competitive landscape in the global sexually transmitted disease (STD) diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Becton Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc., Cepheid (Danaher Corporation), F. Hoffmann-La Roche AG, Hologic Inc., Qiagen N.V., Quidel Corporation, Siemens Healthineers AG (Siemens AG), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.